edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Kazia Therapeutics
Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.
Kazia Therapeutics — 9 videos in collection
Kazia Therapeutics is an oncology focused drug development company based in Sydney, Australia. In addition to Kazia’s lead programme, paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway developed to treat the most common form of brain cancer, the company is developing EVT-801, a small molecule inhibitor of VEGFR3. Preclinical data have shown EVT-801 to be active against a broad range of tumor types.
In this video, Dr James Garner, CEO of Kazia, discusses the rationale behind acquiring the asset, the company’s plans for a Phase I trial and what investors can expect over the next year.
Get access to the very latest content matched to your personal investment style.